AIM ImmunoTech announces issuance of two key U.S. patents

AIM ImmunoTech announced that the U.S. Patent and Trademark Office, USPTO, has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively. AIM Chief Executive Officer Thomas Equels stated: “Our ongoing effort to expand and solidify AIM’s global intellectual property estate is a foundational component of our development strategy for Ampligen. AIM’s expectation for Ampligen – both as a therapeutic for people suffering from dire diseases and as a valuable asset for our stockholders – is the driving force behind our multiple clinical studies in oncology, ME/CFS and Post-COVID conditions. These two new U.S. patents will serve to further strengthen the potential financial future of our company by extending certain sole rights to Ampligen and for these uses to 2039.”